Cesca Therapeutics Appoints Dr. Joseph Thomis to its Board of Directors
January 17, 2017 at 06:00 am
Share
Cesca Therapeutics Inc. announced that Dr. Joseph Thomis will join the company’s Board of Directors. Dr. Thomis brings more than 40 years of experience ranging from drug discovery and clinical development to commercialization. After a short period in Academia, Dr. Thomis went on to play a major role in the development and registration of eight commercially successful cardiovascular and infectious disease products at Bristol-Myers Squibb. He has also held senior clinical development roles at Quintiles, where he was instrumental in the growth of clinical research in Europe. He also specialized in designing and implementing effective regional and global strategies as well as repositioning and restructuring organizations. Dr. Thomis is currently the Non-Executive Director at NovaQuest LLC and Chairman of the Board of Quotient Clinical.
ThermoGenesis Holdings, Inc. develops and commercializes a range of automated technologies for cell-banking, cell-processing, and cell-based therapeutics. The Company provides the AutoXpress and BioArchive platforms for automated clinical bio-banking, the PXP platform for point-of-care cell-based therapies and X-Series products for cell processing services. Its product lines include Clinical Bio-Banking Applications, Point-of-Care Applications and Cell Processing. Its Clinical Bio-Banking Applications include AXP II Automated Cell Separation System and BioArchive Automated Cryopreservation System. Its Point-of-Care Applications include PXP Point-of-Care System, and PXP-1000 System. Its Cell Processing includes X-Series Products for general laboratory use: X-Lab for cell isolation, X-Wash System for cell washing and reformulation, and X-Mini for high efficiency small scale cell purification. The Company markets and sells its medical device products through independent distributors.
THERMOGENESIS HOLDINGS, INC. 
